When a 483 is issued to a medical device company after an inspection, how should the company respond? What should the response contain? What does FDA look for in a 483 response? And how does the company response impact whether the agency will issue a Warning Letter?

At the virtual 2021 FDA/Xavier MedCon conference, FDA Office of Regulatory Affairs (ORA) Office of Medical Device and Radiological Health Operations (OMDRHO), Division 3 compliance officer Jeff Wooley provided insight into the FDA 483 response review process, including what FDA looks for in a response.

[Related: Redica Systems gives you access to FDA 483 observations. To get a “taste” of this rich data, click here to access a FREE 483 Observation Report.]

483 observations specific topic

He introduced the topic by informing the attendees that “a large part of my job as a compliance officer is to review the investigators’ output—their 483s and their EIRs—and determine what regulatory action, if any, we need to take to move toward compliance. In addition to the investigator’s work, a company’s 483 response is a critical part of this review. It can very much impact the final decision—the final recommendation that I make.” The final decision includes whether a Warning Letter will be issued.

In his presentation, Wooley addressed:

  • FDA 483 response policy
  • The Response Letter
  • Agency review process
  • Agency response adequacy determination
  • What documentation to submit with the response
  • Tips for an effective company response

FDA 483 Response Policy

Federal Register 74 FR 40211 outlines the 15 day period that FDA waits for written responses to a 483. It says if a company submits a written response to the agency within 15 business days of receiving a 483, it will include it as part of any regulatory review that is being conducted. In addition to that, FDA will provide acknowledgment of receipt of the response.

“It is very important that you get this within 15 days,” Wooley stressed. “This is voluntary. You do not have to do this. But it will impact the decision that is being made. One caveat to this policy is that if there is a significant public health risk, I do not have to wait the 15 days to make a recommendation. In the device world, that is very rare.

Instructions in this area are also provided in the Investigations Operations Manual, the IOM, which is the primary procedure document for FDA investigators. It directs investigators to inform companies during the closeout meeting that an adequate response may impact the determination or the need for additional action.

[Editor Note: For more about the closeout meeting, read The FDA Inspection is Over: What Happens Next?]

“I think these two policies very clearly show you that we want these responses—that we see they are important and they are a major factor in the agency review,” Wooley said. “We are very much asking for these responses.”

In addition to those policies, another document called the Regulatory Procedures Manual, or RPM, is the primary procedural document for compliance officers. “This document gives me a lot of considerations that I have to make when I am reviewing these cases.”

An excerpt from the Warning Letter section of the RPM discusses factors that need to be considered when the agency is considering issuing a Warning Letter. Three considerations that are directly related to 483 responses are listed:

  • Expectation the firm/persons will take prompt corrective actions
  • Ongoing or promised corrective actions
  • Completed corrective actions

The agency does not expect that within the 15-day timeframe a firm can completely, systemically, and comprehensively correct all the observations that the investigator identified.

“But we do want the response to include a plan of action that you come up with. And if there are any activities that you have started, that you have completed, please include those and evidence of those, because I have to consider that as part of my review.”

“These are the things that are going to make an agency compliance officer comfortable that prompt corrective actions are going to be taken,” he explained.

The phrase “prompt corrective actions” means that the agency needs to see timeframes involved. It needs to see that the resources that are going to be necessary are committed to the project and that the management of the company has buy-in on the corrective actions that are being presented.

The Response Letter

Another section of the RPM discusses a very specific letter that FDA can issue: a Response Letter. 

“When I review the case as a compliance officer, I may feel a Warning Letter needs to be issued,” Wooley explained. “When a response comes in and it mitigates my concerns to a point that I no longer feel a Warning Letter needs to be issued, I can issue what is called a Response Letter.”

Features of a Response Letter:

  • The letter does not contain some of the same penalties as a Warning Letter
  • It is not posted directly to the FDA website
  • It is not going to be part of the consideration for a certificate to a foreign government
  • It is not going to affect a government contract
  • It is a letter saying that essentially the company’s response prevented a Warning Letter from being issued

It contains the same warning statement as in a Warning Letter but essentially will say that if the corrective actions the company has committed to or identified in its response are not followed through, are not completed, or if agency investigators find the same violations at a later date, it may take action without further notice.

Having a section in the RPM on the Response Letter shows this situation happens often enough that it was made part of the agency’s standard operating procedures. Several of these are issued each year across the various FDA inspection programs.

[Related: Click here to access a FREE 483 Observation Report tailored to your team’s needs and see how Redica Systems can save you time.]

483 assessment

The Review Process

Responses are submitted by email. They come to the Director of Compliance Branch (DCB), who will assign them to a compliance officer. Historically, compliance officers did not review every response— they only reviewed responses that were associated with cases recommended for further action. Today they review every response that comes in for any 483.

When a compliance officer reviews a response, the company will get an acknowledgment letter saying the response was received. It is not a substantive review.

Once the compliance officer completes the review, it will be included in whatever communication the agency subsequently sends to the inspected firm. That may be a regulatory action or a letter saying in essence, “the response was good, we will see you next inspection.”

Agency Response Adequacy Determination

Wooley discussed some of the key areas he focuses on when reviewing responses that can have a significant impact on the response adequacy determination. “If these things are not in your response, it could possibly be inadequate,” he commented.

The response needs to address the specific observations that were made by the investigator. For example, if the company was cited for a deficient complaint investigation procedure and was given three examples of complaints identified as not properly investigated, the compliance officer would expect to see that the relevant procedure has been updated and revised appropriately and to see that the three specific examples that were cited have been addressed.

The systemic issues that contributed to the observation and may have impacted product in the field, product in your inventory, other products, other processes, other lines, other quality systems, and subsystems, should be addressed.

“This is by far the most important part of your 483 response,” Wooley pointed out. “This is what is going to weigh the most heavily.”

But we do want the response to include a plan of action that you come up with

Keep in mind that FDA investigators only look at a sampling of records. In the complaint example above, FDA personnel may have looked at 20 complaints, but the firm may have had a thousand complaints that it received over the last few years.

“We would expect to see that you have examined whether there are other complaint investigations that were deficient. We do want to see those. This is a common miss by a lot of companies when they are submitting responses.”
Be sure to include timelines for corrective actions, which need to be realistic and prompt. “I do not want to see that it is going to take two years to update a complaint procedure—that is not reasonable. But I do want to see what the timeframe is and what resources you are devoting to it.”

Submit Corrective Action Evidence

The OMDRHO compliance officer outlined agency expectations for documentation that should accompany a 483 response.

“If you have updated a procedure, if you have redone a validation, I want to see the records that were updated and the procedures that were changed. Please include those so that I can review them to make sure they are adequate and that the work was actually done with data to support these. Include all the supporting data to go with them.”

If the firm did a retrospective complaint review, FDA is interested in how many complaints were examined, how many were deficient, and how many were resolved. If the company completed a new process validation, provide evidence supporting that the validation was correctly done and complete.

“I will also ask for timeframes and plans for recurring progress updates. Those will not affect the adequacy decision,” Wooley explained.

The response needs to address the specific observations that were made by the investigator

“I do not expect all these corrective actions to be completed within that first 15-day response, but I do want to see how often you are going to update me with the actions as you progress. And again, this needs to be reasonable. Most of the time, this is a month to begin with and then most firms will extend it out as we kind of get further down the road and we are just waiting on some bigger hanging issues that are waiting to be resolved.”

It is important to address all discussion items, the compliance officer stressed, noting that failure to do so is another common miss by a lot of firms. FDA does not include certain deficiencies on a 483, he said —for example, 510(k) deficiencies, PMA deficiencies, labeling deficiencies, or certain recall deficiencies— but the investigator will make those discussion items.

“These can often be some of the most significant violations that are identified during the inspection. Make sure you are including responses to discussion items so that we can make sure those are included.”

Five Tips for Effective 483 Responses

Following are Wooley’s Tips for Effective Responses. “These are just ideas to help make sure that I completely and fully understand the response that you have submitted,” he said.

  1. “Include a narrative description of activities. A lot of firms will just submit a handful of procedures and records and expect me to understand and know exactly what was changed and why it was changed. If you do that, it is going to take me a very long time to review because I have to go line by line against what was collected during the inspection to figure that out and I am going to end up having to make a lot of assumptions on what something means and why it was implemented. So narrative descriptions that explain to me what was changed and why it was changed are very, very helpful.
  2. “Please do not bury substantial actions or information that you need an FDA response to, or that are going to require some additional FDA action. For example, if you conduct a recall as part of your corrective actions, please do not put it on page 642 of your response in six-point font. This is a major action that I need to talk with my recall coordinators about. I may need to have conversations with CDRH. Please put that upfront and early to make sure that I see it quickly and soon and can act on it, quickly and soon.
  3. “If you are ceasing production on a certain product, if you are shutting down a facility, if you are going to submit a new 510(k) or a PMA, these are all very important things that I need to know sooner rather than later. So please do not hide them in your response.
  4. “It is very helpful for firms to assemble deliverable tables—a table or graphical representation that identifies the observation each is in response to, the corrective actions that are being taken, and the status of the corrective actions, along with the timeframe. This is a nice, quick reference that helps me quickly update people in the agency, particularly people in the agency that have not viewed the entirety of this response. It helps me explain what is going on including corrective actions quickly and in a nice way.
  5. “All our responses are coming in electronic form. Keep that in mind and try to make them navigable in an electronic format—for example, using bookmarks and links. If you have a very large response, please bookmark the PDF. Links to pages and sections in the document are useful so that I can quickly navigate and identify certain records. Please do not just send a one-thousand-page PDF in which I cannot tell where one document ends and another begins. That is very hard to review and I may misunderstand something in your response.”

Links

Federal Register 74 FR 40211

Investigations Operations Manual

Regulatory Procedures Manual

[Related: Did you know Redica Systems can help you find 483 observations in a specific area? Click here to obtain a FREE 483 Observation Report.]

483 observations report - specific observations

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets
Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.